The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Fintel reports that on March 21, 2025, Benchmark initiated coverage of Kamada (NasdaqGS:KMDA) with a Buy recommendation.

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

After approval by the FDA, AVT03 is expected to be supplied in a single-dose prefilled syringe containing 60 mg in a 1 ml solution, as well as a 120 mg/1.7 ml solution in a single-dose vial.

Sino Biopharm has a good financial position. As of December 2024, it has CNY 9.6 billion in cash on hand and CNY 9.6 billion in debt. Total debt outstanding is 14.7% of its total assets. Its capital ...

Employees at banking giant JPMorgan Chase claimed in a new class action suit that the company mismanaged their benefits, ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX) ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Connor Clark & Lunn Investment Management Ltd. grew its holdings in McKesson Co. (NYSE:MCK – Free Report) by 300.6% during ...

How GLP-1 drugs, regulatory concerns, and more factors are shaping the sector. Plus, 3 undervalued healthcare stocks.

Godrej Properties Ltd has purchased ~10 acres of land in Yelahanka, Bengaluru to develop ~1.5 million square feet of saleable ...